Skip to main content
Premium Trial:

Request an Annual Quote

Roche, SeqWright to Collaborate on Cardio Variants Research

NEW YORK (GenomeWeb News) – Roche today said that it will collaborate with SeqWright and the University of Miami Miller School of Medicine on identifying possible genetic variants associated with dilated cardiomyopathy.

The collaboration will employ NimbleGen's Sequence Capture Human Exome Arrays to enrich more than 180,000 exons from DNA samples taken from people with dilated cardiomyopathy, said Roche. SeqWright will sequence the enriched exons using 454 Life Sciences' Genome Sequencer FLX to detect SNPS, insertions, and deletions.

The collaboration is part of a 15-year study of familial dilated cardiomyopathy being conducted at the Miller School of Medicine.

"We know that familial dilated cardiomyopathy can be explained by mutations in more than 20 autosomal and two X-linked genes, yet mutations in these genes account for only one-third of the cause," Nadine Norton, a research assistant professor at the Miller School of Medicine, said in a statement. "By using an experimental strategy that employs the sequencing of all coding regions within the human genome, we hope to identify other mutations in other genes that cause this terrible disease."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.